Literature DB >> 16460881

Induction of immediate early gene expression by high-frequency stimulation of the subthalamic nucleus in rats.

T Schulte1, S Brecht, T Herdegen, M Illert, H M Mehdorn, W Hamel.   

Abstract

Deep brain stimulation is associated with delayed improvement of parkinsonian symptoms, such as hypokinesia with subthalamic nucleus stimulation, or dystonia with globus pallidus internus stimulation. The latency observed is better explained by molecular alterations than immediate electrophysiological processes, and clinical improvement may involve adaptive gene expression. Here, we have studied immediate early gene expression as fast molecular response to subthalamic nucleus stimulation. Bipolar electrodes were implanted bilaterally into the subthalamic nucleus of anesthetized male Wistar rats. High-frequency stimulation (130 Hz or 80 Hz, 60 micros, 300 microA) or low-frequency stimulation (5 Hz, 60 micros, 300 microA) was performed with the right electrode for 15, 60, 120, and 240 min whereas the silent left electrode served as negative control. Brains were fixed by transcardial perfusion and frozen sections were stained with polyclonal antibodies directed against three immediate early gene-encoded proteins, c-Fos, c-Jun, and Krox-24 (NGFI-A, Egr-1, Zif268, Tis8, Zenk). After 120 and 240 h, c-Fos immunoreactivity was strongly upregulated in subthalamic nucleus neurons on the stimulated site. In contrast, no c-Fos immunoreactivity was detected on the non-stimulated site except for single positive cells located in close proximity to the electrode tracks. Furthermore, c-Fos immunoreactivity was induced in subthalamic nucleus projection areas, such as primary and secondary motor cortex, primary somatosensory and insular cortex, lateral and medial globus pallidus, suprageniculate thalamic nucleus, pontine nuclei, medial geniculate nucleus, and substantia nigra. Similarly, c-Jun and Krox-24 were induced at the site of stimulation and in projection areas following high-frequency subthalamic nucleus stimulation. Whereas high frequency stimulation with 80 Hz was similarly effective none of the three immediate early gene-encoded proteins was induced with low-frequency stimulation (5 Hz) for 4 h. This is in accordance with the therapeutic effects of deep brain stimulation which are only elicited with high frequency stimulation. Our data provide evidence that immediate early gene expression in the subthalamic nucleus is rapidly and substantially induced by high-frequency stimulation. The induction of immediate early genes in projection sites suggests ipsilateral transsynaptic modulation of neuronal activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460881     DOI: 10.1016/j.neuroscience.2005.12.034

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

Review 1.  Mechanisms and targets of deep brain stimulation in movement disorders.

Authors:  Matthew D Johnson; Svjetlana Miocinovic; Cameron C McIntyre; Jerrold L Vitek
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

2.  The rewarding and locomotor-sensitizing effects of repeated cocaine administration are distinct and separable in mice.

Authors:  Thorfinn T Riday; Barry E Kosofsky; C J Malanga
Journal:  Neuropharmacology       Date:  2011-12-16       Impact factor: 5.250

3.  Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.

Authors:  Meaghan C Creed; Clement Hamani; Alanna Bridgman; Paul J Fletcher; José N Nobrega
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

4.  Development of a Fully Implantable Stimulator for Deep Brain Stimulation in Mice.

Authors:  Michael Fleischer; Heinz Endres; Michael Sendtner; Jens Volkmann
Journal:  Front Neurosci       Date:  2020-07-21       Impact factor: 4.677

5.  EEG power asymmetry and functional connectivity as a marker of treatment effectiveness in DBS surgery for depression.

Authors:  Maher A Quraan; Andrea B Protzner; Zafiris J Daskalakis; Peter Giacobbe; Chris W Tang; Sidney H Kennedy; Andres M Lozano; Mary P McAndrews
Journal:  Neuropsychopharmacology       Date:  2013-11-28       Impact factor: 7.853

6.  An accurate method for the quantification of cytochrome C oxidase in tissue sections.

Authors:  Miguel Melendez-Ferro; Matthew W Rice; Rosalinda C Roberts; Emma Perez-Costas
Journal:  J Neurosci Methods       Date:  2013-01-30       Impact factor: 2.390

7.  Optimizing a rodent model of Parkinson's disease for exploring the effects and mechanisms of deep brain stimulation.

Authors:  Karl Nowak; Eilhard Mix; Jan Gimsa; Ulf Strauss; Kiran Kumar Sriperumbudur; Reiner Benecke; Ulrike Gimsa
Journal:  Parkinsons Dis       Date:  2011-04-05

8.  Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus.

Authors:  Anton Fomenko; Darrin J Lee; Chris McKinnon; Eun Jung Lee; Mitchell L de Snoo; Elise Gondard; Clemens Neudorfer; Clement Hamani; Andres M Lozano; Lorraine V Kalia; Suneil K Kalia
Journal:  Front Neurosci       Date:  2020-05-12       Impact factor: 4.677

9.  High-frequency stimulation of the subthalamic nucleus counteracts cortical expression of major histocompatibility complex genes in a rat model of Parkinson's disease.

Authors:  Benjamin Grieb; Gerhard Engler; Andrew Sharott; Constantin von Nicolai; Thomas Streichert; Ismini Papageorgiou; Alexander Schulte; Manfred Westphal; Katrin Lamszus; Andreas K Engel; Christian K E Moll; Wolfgang Hamel
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 10.  Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease.

Authors:  Nathan C Rowland; Suneil K Kalia; Lorraine V Kalia; Paul S Larson; Daniel A Lim; Krystof S Bankiewicz
Journal:  Mol Ther Methods Clin Dev       Date:  2016-01-13       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.